✦ LIBER ✦

Adjuvant therapy with high-dose medroxyprogesterone acetate for operable breast cancer

✍ Scribed by Hiroki Koyama; Breast Cancer Collaborative Group for Medroxyprogesterone Acetate

Publisher: Springer Japan
Year: 1999
Tongue: English
Weight: 771 KB
Volume: 6
Category: Article
ISSN: 1340-6868
DOI: 10.1007/bf02966915

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacoclinical data on high dose medro

Pharmacoclinical data on high dose medroxyprogesterone acetate in advanced breast cancer

✍ Moise Namer; Gérard Milano; Roger Khater; Marc Frenay; Antoine Thyss; Nicole Ren 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 228 KB

The pharmacokinetics of high-dose medrox

The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer

✍ Hans Christian Blossey; Hans Helge Bartsch; Dietrich Kanne; Johannes Koebberling 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 425 KB

Oral high-dose medroxyprogesterone aceta

Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer

✍ Masaru Izuo; Yuichi Iino; Keiichi Endo 📂 Article 📅 1981 🏛 Springer US 🌐 English ⚖ 510 KB

Adrenal suppression by oral high-dose me

Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients

✍ Henk Veelen; Pax H. B. Willemse; Dirk T. Sleijfer; John J. Pratt; Wim J. Sluiter 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 332 KB

The effects of oral MPA, 300 mg t.i.d., on adrenal function in postmenopausal patients with disseminated breast cancer were evaluated. The levels of serum cortisol, ACTH, androstenedione, DHEA-S, LH, FSH, GH, and prolactin in 22 patients receiving MPA were compared with those in another group of 28

Pharmacokinetic and pharmacodynamic basi

Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate

✍ Hans Christian Blossey; Hans Erik Wander; Johannes Koebberling; Professor Dr. Ge 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 728 KB

Postmenopausal patients with metastatic breast cancer were treated with medroxyprogesterone acetate (MPA) (Clinovir) in dosages between 500 and 1500 mg orally per day. The relation of MPA plasma concentrations and endocrine effects were studied in a longitudinal fashion. MPA exerted suppressive effe

A phase II study of high-dose medroxypro

A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer

✍ Geoffrey Falkson; Hèndré C. Falkson 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high